dc.contributor.author |
Zarura, Shafea |
|
dc.date.accessioned |
2020-07-13T12:58:07Z |
|
dc.date.available |
2020-07-13T12:58:07Z |
|
dc.date.issued |
2018 |
|
dc.identifier.citation |
ZARURA, Shafea. Contemporary management of obesity. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 279. |
en_US |
dc.identifier.uri |
https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf |
|
dc.identifier.uri |
http://repository.usmf.md/handle/20.500.12710/11289 |
|
dc.description |
Department of Pharmacology
and Clinical Pharmacy,
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova |
en_US |
dc.description.abstract |
Introduction. Obesity has become a serious public health problem in most industrialized
countries, affecting a growing segment of the population.
Aim of the study. Study of etiopathogenetic factors, consequences and strategies of obesity
treatment in Moldova and Israel.
Materials and methods. 220 patients overweight were evaluated in 2017 aged 40-79. I used the
questionnaire to investigate clinical cases.
Results. Our group is made up of 30% male subjects and the vast majority of 70% of female
subjects. 76% of the subjects in the control group claim 3-5 meals per day, 13% consume 2-3
meals / day and only 14% - between 5-7 meals / dayIt is noticed that 55% of patients have a
sedentary activity at work 40% of people were diagnosed but dyslipidemia, 20% with diabetes,
15% with hypertension, and 25% with associated diseases. It was found that 37% of patients
were treated with Orlistat and 19% with Lorcaserin, of which 49% of patients treated with
Orlistat and 40% of patients treated with Lorcaserin lost ≥ 10% of baseline body weight after 6
months of treatment, the mean weight difference between these preparations being 3.2 kg.
Conclusions. Obesity is associated with numerous complications, such as dyslipidemia,
diabetes, hypertension, etc. After 6 months of treatment, the mean difference in weight loss of
Orlistat and Lorcaserin was 3.2 kg. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
MedEspera |
en_US |
dc.subject |
obesity |
en_US |
dc.subject |
Orlistat |
en_US |
dc.subject |
Lorcaserina |
en_US |
dc.title |
Contemporary management of obesity |
en_US |
dc.type |
Article |
en_US |